Your browser doesn't support javascript.
loading
Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study.
Sekmek, Serhat; Karahan, Irfan; Ucar, Gokhan; Ceylan, Furkan; Bayram, Dogan; Seven, Ismet; Bölek, Hatice; Ürün, Yüksel; Yücel, Kadriye Bir; Yazici, Ozan; Kadioglu, Ahmet; Karacin, Cengiz; Canaslan, Kubra; Atag, Elif; Demirer, Serhat; Erdem, Gokmen Umut; Ergun, Yakup; Atak, Mehmetcan; Koksal, Baris; Kiran, Merve Meryem; Turkay, Duriye Ozer; Civelek, Burak; Yalcin, Bulent; Uncu, Dogan.
Afiliação
  • Sekmek S; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey. serhatsekmek@gmail.com.
  • Karahan I; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Ucar G; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Ceylan F; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Bayram D; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Seven I; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Bölek H; Department of Medical Oncology, Ankara University, Ankara, Turkey.
  • Ürün Y; Department of Medical Oncology, Ankara University, Ankara, Turkey.
  • Yücel KB; Department of Medical Oncology, Gazi University, Ankara, Turkey.
  • Yazici O; Department of Medical Oncology, Gazi University, Ankara, Turkey.
  • Kadioglu A; Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
  • Karacin C; Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
  • Canaslan K; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkey.
  • Atag E; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkey.
  • Demirer S; Department of Medical Oncology, Istanbul Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
  • Erdem GU; Department of Medical Oncology, Istanbul Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
  • Ergun Y; Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey.
  • Atak M; Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey.
  • Koksal B; Department of Medical Oncology, Hacettepe University, Ankara, Turkey.
  • Kiran MM; Department of Pathology, Ankara City Hospital, Ankara, Turkey.
  • Turkay DO; Department of Pathology, Ankara City Hospital, Ankara, Turkey.
  • Civelek B; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Yalcin B; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Uncu D; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
Clin Transl Oncol ; 26(8): 1878-1885, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38451412
ABSTRACT

AIM:

HER2-positive metastatic gastric cancer is still a highly fatal disease despite advances. We aimed to investigate the relationship between HER2/CEP17 ratio and survival in patients with HER2-positive metastatic gastric cancer.

METHODS:

A total of 99 patients from 8 different centers in Turkey were included in the study. Patients with HER2-positive metastatic gastric cancer and whose HER2/CEP17 ratio was examined were included in the study. Patients were divided into two groups according to HER2/CEP17 values, and survival analysis was performed.

RESULTS:

The median age was 64 (24-83) years. There were 74 (74.8%) male and 25 (25.2%) female patients. OS in the high HER2/CEP17 ratio group was 21.97 months (95% CI 16.36-27.58), and in the low ratio group was 16.17 months (95% CI 10.95-21.38) (p = 0.015). OS was 17.7 months (95% CI 7.02-28.37) in the high HER2 gene copy number group and 10.13 months (5.55-14.71) in the group with low copy number (p = 0.03). PFS was 10.94 months (95% CI 7.55-14.33) in the group with high HER2 gene copy number and 7.56 months (4.62-10.49) in the low copy number group (p = 0.06).

CONCLUSION:

Patients with both high HER2 gene amplification and high HER2/CEP17 ratio had better OS. The PFS of the group with high HER2 gene amplification was also better. To our knowledge, this is the first study in the literature showing that the HER2/CEP17 ratio affects survival in patients with metastatic gastric cancer.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Receptor ErbB-2 Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Turquia País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Receptor ErbB-2 Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Turquia País de publicação: Itália